Company Number: 15054361

Analysis Date: 2025-07-20 13:01 UTC

Credit Opinion:
CONDITIONAL APPROVAL. SR Treatment Solutions Ltd is a newly incorporated micro-entity operating in specialist medical practice activities. The company has minimal financial history, limited assets, and modest working capital. While currently solvent with positive net assets, its ability to service debt depends heavily on future cash flow generation given the tight liquidity position. Credit approval should be conditional on receiving updated management accounts and monitoring short-term cash flow closely.

Financial Strength:

• Fixed assets stand at £11,137, reflecting modest investment in long-term resources.
• Current assets are £62,833, nearly offset by current liabilities of £61,589, resulting in net current assets of only £1,244. This indicates very limited working capital buffer.
• Shareholders’ funds (equity) are £12,381, showing a small but positive net asset base.
• The company employs 2 staff including the director, suggesting a small operational scale.
• The director also owes the company £317, interest-free, which is a minor receivable.

Cash Flow Assessment:

• The narrow net current assets margin signals tight liquidity, with current liabilities nearly equal to current assets. This suggests limited capacity to absorb unexpected cash outflows or delays in receivables.
• Absence of a profit and loss account in the filing limits insight into operational cash flow and profitability.
• Given the company’s very recent incorporation (August 2023) and micro-entity status, cash flow volatility is a risk, and ongoing monitoring is critical.

Monitoring Points:

• Obtain and review interim management accounts to assess revenue generation and operating cash flow trends.
• Monitor changes in working capital, especially receivables and payables cycles, to ensure liquidity remains sufficient.
• Watch for any credit exposure increases or additional borrowing that could strain the company’s limited equity base.
• Track director conduct and related party transactions, though current records show no adverse issues.
• Review sector outlook for specialist medical practices to gauge external risks.